Research programme: neurodegenerative disorders diagnostic imaging - Piramal Healthcare

Drug Profile

Research programme: neurodegenerative disorders diagnostic imaging - Piramal Healthcare

Alternative Names: 18F-Deprenyl

Latest Information Update: 13 Nov 2014

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neurodegenerative disorders

Most Recent Events

  • 13 Nov 2014 Research programme: neurodegenerative disorders diagnostic imaging - Piramal Healthcare is available for licensing as of 13 Nov 2014. http://piramal.com/piramal-enterprises/piramal-capital
  • 13 Nov 2014 Preclinical development is ongoing in Germany
  • 15 Apr 2012 Piramal Healthcare has acquired the molecular imaging research and development portfolio of Bayer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top